Tracking H1N1 as Americans Prepare for Holiday Travel
Here at the FOX News bureau in Atlanta, we’re awaiting a 12 PM Eastern media briefing from the Centers for Disease Control and Prevention. Anne Schuchat, MD, director of the CDC’s National Center for Immunization and Respiratory Diseases is scheduled to update reporters on the latest H1N1 activity and the distribution of vaccine.
Last week, the CDC reported a downward trend in influenza activity, but cautioned that it was too early to declare the worst was over. Health experts say holiday travel may cause temporary spikes.
AAA projects 38.4 million Americans will travel at least 50 miles from home over the Thanksgiving holiday (a 1.4 percent increase over last year when Thanksgiving travel decreased by more than 25 percent amid concerns over the economic meltdown),
In addition to the usual recommendations to wash hands, cover coughs and get vaccinated as soon as possible, the CDC is urging people not to travel if they’re sick.
As of yesterday, 49,584,300 doses of H1N1 vaccine have shipped nationwide, according to flu.gov.
Although state health departments continue to focus vaccination campaigns on high risk groups, such as children, health care workers, pregnant women and persons with underlying health conditions, Pennsylvania Gov. Ed Rendell told reporters, vaccine could become available to the general public within the next few weeks.
Canadian health officials have advised doctors in that country to stop using a specific batch of H1N1 vaccine, representing 170 thousand doses, after half a dozen patients had severe allergic reactions. A CDC spokesman says the batch in question is an adjuvanted version of the H1N1 vaccine that is not distributed in the US.
Adjuvants are ingredients added to a vaccine to increase the body’s immune response, which often allows for the use of smaller doses — thereby extending limited vaccine supplies. Although widely used in Europe, Asia and Canada, adjuvants are not currently authorized for use in influenza vaccines here in the US.
Experts say it’s still unclear whether adjuvants played a role in the adverse reactions, or whether some other factor came into play.
Meanwhile, China has reported eight cases of H1N1 mutation. However, Chinese health officials say the variant form of the virus is still prevented by vaccines and responds to anti-viral drugs.
And four patients in an isolated unit at Duke University Medical Center have contracted a strain of H1N1 that shows resistance to Tamiflu, a leading anti-viral drug. However, doctors say this new form of the virus is no more severe than the original.
Early on, researchers warned that the H1N1 virus could mutate or develop resistance to anti-viral drugs. So far, variant forms of the virus do not appear to be in wide circulation.